Indian biopharmaceutical major Suven Life Sciences Ltd has been granted one product patent each in Australia and the US for its molecules that will help in the treatment of neurodegenerative disorders like Alzheimer’s disease, Parkinson and Schizophrenia.
The product patent from Australia (2014358652) and from the US (9636335) will be valid through 2032 and 2034 respectively, said the Hyderabad-based company which was incorporated in 1989, Suven said in a Bombay Stock Exchange (BSE) filing.
Suven CEO Venkat Jasti said he was “very pleased” by the development, adding that Suven’s pipeline of molecules in the central nervous system arena will help treat cognitive disorders, which has a huge market potential globally owing to “high unmet medical need”.
Suven is developing the class of selective 5HT6 and 5HT4 compounds as therapeutic agents to treat Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
Suven Life Science is focused on discovering, developing and commercialising novel pharmaceutical products.